Saturday 17 October 2026
Export PTIX’s income statement to Excel — free account
Atrinsic Inc.
PTIX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 61.3% and free cash flow grew 46.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.75
0.05
−6.25%
Follow PTIX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (338.24%) | 75.33% | 616.14% | 420.53% |
+8 more TTM periods Free account |
|
| 378.63% | 53.04% | (174.84%) | (216.78%) | ||
ROIC |
(229.86%) | (253.66%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,532.09%) | 260.22% | 114.94% | 120.95% | |
Average Days of Receivables |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.10) | (1.27) | (2.14) | (2.15) | |
Free Cash Flow |
(2.00) | (2.96) | (4.14) | (3.98) | |
Capital Expenditures |
— | (0.15) | — | — | |
| Other line items | |||||
Cash ROIC |
(87.36%) | (71.74%) | 2,298.89% | 201.42% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | (2.44) | (6.32) | (4.15) | |
Operating CF/Net income |
(0.37) | (2.05) | 0.80 | 0.48 | |
Depreciation/Fixed assets |
220.82 | 110.73 | 7.57 | 8.97 | |
Capex/Depreciation |
0.00 | (0.10) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.10) | (1.21) | (2.14) | (2.15) | |
Capex per Share |
0.00 | (0.07) | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates · fundamentals updated 28 Sep 2026